Retinal pigment epithelial tears after single administration of intravitreal bevacizumab for neovascular age-related macular degeneration

Eye

Volumn 23, Issue 3, 2009, Pages 694-702

  Gelisken, F ^a   Ziemssen, F ^a   Voelker, M ^a   Bartz Schmidt, K U ^a   Inhoffen, W ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Age related macular degeneration; Bevacizumab; Choroidal neovascularization; Complication; Retinal pigment epithelial tear; Vascular endothelial growth factor

Indexed keywords

BEVACIZUMAB; ANGIOGENESIS INHIBITOR; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; FEMALE; FIBROSIS; FLUORESCENCE ANGIOGRAPHY; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; OPTICAL COHERENCE TOMOGRAPHY; RETINA HEMORRHAGE; RETINA MACULA AGE RELATED DEGENERATION; RETINA TEAR; SUBRETINAL NEOVASCULARIZATION; VISUAL ACUITY; CHEMICALLY INDUCED; CHOROIDAL NEOVASCULARIZATION; COMPLICATION; DRUG ADMINISTRATION; DRUG EFFECTS; EPIDEMIOLOGY; INTRAOCULAR DRUG ADMINISTRATION; MACULAR DEGENERATION; MIDDLE AGED; PATHOLOGY; PIGMENT EPITHELIUM; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; CHOROIDAL NEOVASCULARIZATION; DRUG ADMINISTRATION SCHEDULE; EPIDEMIOLOGIC METHODS; FEMALE; HUMANS; INJECTIONS, INTRAOCULAR; MACULAR DEGENERATION; MALE; MIDDLE AGED; RETINAL HEMORRHAGE; RETINAL PERFORATIONS; RETINAL PIGMENT EPITHELIUM;

EID: 62549090117     PISSN: 0950222X     EISSN: 14765454     Source Type: Journal    
DOI: 10.1038/sj.eye.6703098     Document Type: Article

References (39)

1. Klein R, Klein BEK, Linton KLP. Prevalence of age-related maculopathy. The beaver dam eye study. Ophthalmology 1992; 99: 933-943.
2. Kvanta A, Algvere PV, Berglin L, Seregard S. Subfoveal fibrovascular membranes in age-related macular degeneration expresses vascular endothelial growth factor. Invest Ophthalmol Vis Sci 1996; 37: 1929-1934.
3. Kliffen M, Sharma HS, Mooy CM, Kerkvliet S, de Jong PT. Increased expression of angiogenic growth factors in agerelated maculopathy. Br J Ophthalmol 1997; 81: 154-162.
4. Krzystolik MG, Afshari MA, Adamis AP, Gaudreault J, Gragoudas ES, Michaud NA et al. Prevention of experimental choroidal neovascularization with intravitreal antivascular endothelial growth factor antibody fragment. Arch Ophthalmol 2002; 120: 338-346.
5. Gragoudas ES, Adamis AP, Cunningham Jr ET, Feinsod M, Guyer DR. VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004; 351: 2805-2816.
6. Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006; 355: 1432-1444.
7. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006; 355: 1419-1431.
8. Rosenfeld PJ, Moshfeghi AA, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for neovascular agerelated macular degeneration. Ophthalmic Surg Lasers Imaging 2005; 36: 331-335.
9. Avery RL, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, Giust MJ. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 2006; 113: 363-372.
10. Bashshur ZF, Bazarbachi A, Schakal A, Haddad ZA, El Haibi CP, Noureddin BN. Intravitreal bevacizumab for the management of choroidal neovascularization in age-related macular degeneration. Am J Ophthalmol 2006; 142: 1-9.
11. Spaide RF, Laud K, Fine HF, Klancnik Jr JM, Meyerle CB, Yannuzzi LA et al. Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina 2006; 26: 383-390.
12. Rich RM, Rosenfeld PJ, Puliafito CA, Dubovy SR, Davis JL, Flynn Jr HW et al. Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular agerelated macular degeneration. Retina 2006; 26: 495-511.
13. Luke M, Warga M, Ziemssen F, Gelisken F, Grisanti S, Schneider T et al. Effects of bevacizumab on retinal function in isolated vertebrate retina. Br J Ophthalmol 2006; 90: 1178-1182, . e-pub 5 June 2006.
14. Maturi RK, Bleau LA, Wilson DL. Electrophysiologic findings after intravitreal bevacizumab (Avastin) treatment. Retina 2006; 26: 270-274.
15. Nicolo M, Ghiglione D, Calabria G. Retinal pigment epithelial tear following intravitreal injection of bevacizumab (Avastin). Eur J Ophthalmol 2006; 16: 770-773.
16. Meyer CM, Mennel S, Schmidt JS, Kroll P. Acute retinal pigment epithelial tear following intravitreal bevacizumab (Avastin) injection for occult choroidal neovascularisation secondary to age related macular degeneration. Br J Ophthalmol 2006; 90: 1207-1208.
17. Bakri SJ, Patel SP. Retinal pigment epithelial tear following intravitreal bevacizumab. Eye 2007; 21: 424-425.
18. Gelisken F, Ziemssen F, Voelker M, Bartz-Schmidt KU. Retinal pigment epithelial tear following intravitreal bevacizumab injection for neovascular age-related macular degeneration. Acta Ophthalmol Scand 2006; 84: 833-834.
19. Spandau UH, Jonas JB. Retinal pigment epithelium tear after intravitreal bevacizumab for exudative age-related macular degeneration. Am J Ophthalmol 2006; 142: 1068-1070.
20. Shah CP, Hsu J, Garg SJ, Fischer DH, Kaiser R. Retinal pigment epithelial tear after intravitreal bevacizumab injection. Am J Ophthalmol 2006; 142: 1070-1072.
21. Gamulescu MA, Framme C, Sachs H. RPE-rip after intravitreal bevacizumab (Avastin) treatment for vascularised PED secondary to AMD. Graefes Arch Clin Exp Ophthalmol 2007; 245: 1037-1040, e-pub 21 February 2007.
22. Chang LK, Sarraf D. Tears of the retinal pigment epithelium. An old problem in a new Era. Retina 2007; 27: 523-534.
23. Ronan SM, Yoganathan P, Chien FY, Corcostegui IA, Blumenkranz MS, Deramo VA et al. Retinal pigment epithelium tears after intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration. Retina 2007; 27: 535-540.
24. Chan CK, Meyer CH, Gross JG, Abraham P, Nuthi AS, Kokame GT et al. Retinal pigment epithelial tears after intravitreal bevacizumab injection for neovascular agerelated macular degeneration. Retina 2007; 27: 541-551.
25. Shabeeba R, Hannan SR, Madhusudhana KC, Lotery AJ, Newsom RSB. Retinal pigment epithelial tear following bevacizumab for choroidal neovascular membrane due to age-related macular degeneration. Br J Ophthalmol 2007; 91: 977-978.
26. Mathews JP, Jalil A, Lavin MJ, Stanga PE. Retinal pigment epithelial tear following intravitreal injection of bevacizumab (avastin): optical coherence tomography and fluorescein angiographic findings. Eye 2007; 21: 1004-1005.
27. Macular Photocoagulation Study Group. Subfoveal neovascular lesions in age-related macular degeneration: guidelines for evaluation and treatment in the Macular Photocoagulation Study. Arch Ophthalmol 1991; 109: 1242-1257.
28. Verteporfin Roundtable Participants. Guidelines for using verteporfin (Visudyne) in photodynamic therapy for choroidal neovascularization due to age-related macular degeneration and other causes: update. Retina 2005; 25: 119-134.
29. Hoskin A, Bird AC, Sehmi K. Tears of detached retinal pigment epithelium. Br J Ophthalmol 1981; 65: 859-865.
30. Gass JD. Retinal pigment epithelial rip during krypton red laser photocoagulation. Am J Ophthalmol 1984; 98: 700-706.
31. Gelisken F, Inhoffen W, Partsch M, Schneider U, Kreissig I. Retinal pigment epithelial tear after photodynamic therapy for choroidal neovascularization. Am J Ophthalmol 2001; 131: 518-520.
32. Goldstein M, Heilweil G, Barak A, Loewenstein A. Retinal pigment epithelial tear following photodynamic therapy for choroidal neovascularization secondary to AMD. Eye 2005; 19: 1315-1324.
33. Dhalla MS, Blinder KJ, Tewari A, Hariprasad SM, Apte RS. Retinal pigment epithelial tear following intravitreal pegaptanib sodium. Am J Ophthalmol 2006; 141: 752-754.
34. Amselem L, Pulido JS, Diaz-Llopis M, Cervera E, Montero J. Retinal pigment epithelial tear following ranibizumab use. Eye 2007; 21(6): 846-847, e-pub ahead of print 26 January.
35. Casswell AG, Kohen D, Bird AC. Retinal pigment epithelial detachments in the elderly: classification and outcome. Br J Ophthalmol 1985; 69: 397-403.
36. Pauleikhoff D, Loeffert D, Spital G, Radermacher M, Dohrmann J, Lommatzsch A et al. Pigment epithelial detachment in elderly. Clinical differentiation, natural course and pathogenetic implications. Graefes Arch Clin Exp Ophthalmol 2002; 533-538.
37. Chuang EL, Bird AC. Bilaterality of tears of the retinal pigment epithelium. Br J Ophthalmol 1988; 72: 918-920.
38. Reynders S, Lafaut BA, Aisenbrey S, Broecke CV, Lucke K, Walter P et al. Clinicopathologic correlation in hemorrhagic age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 2002; 240: 279-285.
39. Scupola A, Coscas G, Soubrane G, Balestrazzi E. Natural history of macular subretinal hemorrhage in age-related macular degeneration. Ophthalmologica 1999; 213: 97-102.